660852-86-8

Basic information

• Product Name: (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER
• Synonyms: (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER;(R)-3-(TERT-BUTOXYCARBONYL)-2,2-DIMETHYLOXAZOLIDINE-4-CARBOXYLIC ACID
• CAS NO: 660852-86-8
• Molecular Formula: C₁₁H₁₉NO₅
• Molecular Weight: 245.27
• Product Categories: pharmacetical
• Mol File: 660852-86-8.mol

Chemical Properties

• Boiling Point: 358.2±42.0 °C(Predicted)
• Appearance: /
• Density: 1.175±0.06 g/cm3(Predicted)
• PKA: 3.55±0.40(Predicted)
• CAS DataBase Reference: (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER(660852-86-8)
• EPA Substance Registry System: (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER(660852-86-8)

Safety Data

• Hazardous Substances Data: 660852-86-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical and Medicinal Chemistry:
(R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER is used as a chiral building block for the synthesis of other compounds, particularly in the development of pharmaceuticals and medicines. Its unique stereochemistry allows for the creation of enantiomerically pure compounds, which is essential for ensuring the desired biological activity and reducing potential side effects.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER serves as a valuable intermediate, facilitating the construction of complex molecular structures. Its presence can enhance the efficiency and selectivity of various chemical reactions, contributing to the advancement of synthetic methodologies.
Used in Drug Discovery:
(R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER is utilized in drug discovery processes, where its potential biological activity and pharmacological effects are explored. Researchers investigate its interactions with biological targets to identify new therapeutic agents or optimize existing ones.
Used as a Chiral Resolving Agent:
In the context of chiral chemistry, (R)-2,2-DIMETHYL-OXAZOLIDINE-3,4-DICARBOXYLIC ACID 3-TERT-BUTYL ESTER can be employed as a chiral resolving agent. This application is vital for the separation and purification of enantiomers, ensuring that only the desired stereoisomer is obtained for use in pharmaceuticals or other applications where stereochemistry plays a critical role.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 3262-72-4 (R)-N-tert-butoxycarbonyl serine 
• 77-76-9 2,2-dimethoxy-propane 
• 83345-44-2 3-tert-butoxycarbonylamino-4-hydroxy-butyric acid 
• 136703-59-8 (3S)-3-[(tert-butoxycarbonyl)amino]-4-hydroxybutanoic acid methyl ester 
• 95715-85-8 2-(tert-butoxycarbonylamino)-3-hydroxypropionic acid methyl ester 
• 108149-60-6 methyl [(4R)-3-(tert-butoxycarbonyl)-2,2-dimethyl-1,3-oxazolidin-4-yl]carboxylate 

Downstream Products

• 896746-83-1 (R)-4-(2-benzoyl-phenylcarbamoyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid tert-butyl ester 
• 1822572-30-4 4-(methoxymethylcarbamoyl)-2,2-dimethyloxazolidine-3-carboxylic acid tert-butyl ester 
• 1310683-93-2 C₁₉H₂₆N₂O₅ 
• 95715-87-0 (R)-3-tert-butoxycarbonyl-4-formyl-2,2-dimethyloxazolidine 
• 167102-62-7 (R)-N,O-isopropylidenyl-2-(N-tert-butyloxycarbonylamino)-3-oxo-propanamide-N,O-dimethyl-hydroxyamine 
• 1443753-94-3 C₁₈H₂₅NO₆ 
• 1443753-93-2 (3S,4S)-benzyl N,O-isopropylidenyl-4-(N-tert-butyloxycarbonylamino)-3-methyl-5-oxopentanoate 
• 167102-63-8 (R)-N,O-isopropylidenyl-4-(N-tert-butyloxycarbonylamino)-3-oxo-2-butanone 
• 1308272-25-4 C₃₉H₄₆BrF₂NO₉ 
• 1242185-13-2 (R)-tert-butyl 4-(2-benzoyl-4-chlorophenylcarbamoyl)-2,2-dimethyloxazolidine-3-carboxylate 
• 1242185-14-3 (R)-tert-butyl 4-(2-(4-bromobenzoyl)phenylcarbamoyl)-2,2-dimethyloxazolidine-3-carboxylate 

Relevant articles and documents

ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta- associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

NOVEL PROCESS FOR THE PREPARATION OF (R)-N-BENZYL-2-ACETAMIDO-3-METHOXYPROPIONAMIDE

The invention is a novel process for the preparation of lacosamide by employing novel intermediates of formula III and IV:

Synthesis of a novel series of 2,3,4-trisubstituted oxazolidines designed by isosteric replacement or rigidification of the structure and cytotoxic evaluation

We have previously reported on a study of the structure-activity relationship in a series of 2,3,4-substituted oxazolidines recently discovered by our group varying the substituent at the ring or stereochemistry of the oxazolidine ring. We discovered the cytotoxic and pro-apoptotic potential of compounds 1 and 2 with good selectivity against cancer cell lines. In the present study we describe the synthesis and cytotoxic evaluation against cancer cell lines (HL60, JURKAT, MDA-MB-231 and LNCaP) of a series of oxazolidines designed by isosteric replacement or rigidification of the oxymethylene spacer of compounds 1 and 2. Alkenes 3 and 4 retained the activity against MDA-MB-231 cells and they were more active on HL60, JURKAT and LNCaP cells. Considering LNCaP cells, E-isomer 4 was at least 7 times and about 3 times more potent than lead 1 and Z-isomer 3, respectively. Compound 4 exerted significant activity against LNCaP with IC50 in the low micromolar range (11 μM) without affecting VERO cells and PBMC proliferation (IC50 > 100 μM) indicating its low toxicity to normal cells.

NMR characterization and conformational analysis of a potent papain-family cathepsin L-like cysteine protease inhibitor with different behaviour in polar and apolar media

We recently reported the synthesis, of a potent papain-family cathepsin L-like cysteine protease inhibitor, as new lead compound for the development of new drugs that can be used as antiprotozoal agents. The investigation of its conformational profile is

Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position

Protein-protein interactions (PPIs) mediated by the polo-box domain (PBD) of polo-like kinase 1 (Plk1) serve important roles in cell proliferation. Critical elements in the high affinity recognition of peptides and proteins by PBD are derived from pThr/pS

Development of peptidomimetics with a vinyl sulfone warhead as irreversible falcipain-2 inhibitors

This paper describes the synthesis of a new class of peptidomimetic cysteine protease inhibitors based on a 1,4-benzodiazepine scaffold and on an electrophilic vinyl sulfone moiety. The former was introduced internally to a peptide sequence that mimics th

Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents

The synthesis of a new class of peptidomimetics 1a-j, based on a 1,4-benzodiazepine scaffold and on a C-terminal aspartyl aldehyde building block, is described. Compounds 1a-j provided significant inhibitory activity against falcipains 2A and 2B (FP-2A an

Synthesis of C-glycosyl amino acids: Scope and limitations of the tandem Tebbe/Claisen approach

Amino acids may be used as coupling partners for esterification with 3-hydroxy glycals as substrates for the tandem Tebbe/Claisen approach to the synthesis of C-glycosyl amino acids. Whilst esters of substituted α-amino acids do not successfully undergo T

Derivatives of glycinergic r(+)-2-amino-3-hydroxypropanoic acid

The use of R(+)-2-amino-3-hydroxypropanoic acid derivatives, nitrogen substituted by a (C1-C6)alkyl, (C3-C6)alkenyl, 3-oxo(C5-C6)alkyl, 3-oxo(C4-C6)alken-2-yl, phenyl(